TriSalus Life Sciences, Inc. (TLSI)
USD 3.76
(-1.31%)
USD 3.76
(-1.31%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -50.04 Million | -32.31 Million | -22.69 Million | -677.59 Thousand |
| Net Income | -59.03 Million | -47.18 Million | -28.84 Million | -711.38 Thousand |
| Depreciation & Amortization | 702 Thousand | 398 Thousand | 464 Thousand | 321 Thousand |
| Deferred income taxes | 11.08 Million | 310 Thousand | -832 Thousand | - |
| Stock-based compensation | 1.4 Million | 368 Thousand | 109 Thousand | 22 Thousand |
| Change in working capital | 740 Thousand | 2.3 Million | -131 Thousand | -569.98 Thousand |
| Other non-cash items | -4.94 Million | 11.49 Million | 6.53 Million | 603.77 Thousand |
| Investing Cash Flow | -2.12 Million | -1.78 Million | -2.25 Million | -250 Million |
| Investments in PPE | -1.12 Million | -786 Thousand | -1.25 Million | -545 Thousand |
| Acquisitions | -1 Million | -1 Million | -1 Million | - |
| Investment purchases | - | - | - | -250 Million |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -1 Million | -1 Million | -1 Million | -9.15 Million |
| Financing Cash Flow | 54.62 Million | 13.46 Million | 50.76 Million | 252.01 Million |
| Debt repayment | -87 Thousand | -131 Thousand | -1.34 Million | -178.08 Thousand |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | -20 Thousand | - | - | - |
| Common Stock Issuance | 17.88 Million | 13.59 Million | - | 252.19 Million |
| Other Financing Activities | 35.73 Million | 13.59 Million | 52.11 Million | 27 Thousand |
| Accounts receivables | -1.97 Million | -200 Thousand | -741 Thousand | -423 Thousand |
| Accounts payables | 2.83 Million | 5.24 Million | 3.17 Million | - |
| Inventory | -1.07 Million | -179 Thousand | -725 Thousand | 755 Thousand |
| Other working capital | 953 Thousand | -2.56 Million | -1.84 Million | -569.98 Thousand |
| Cash at beginning of period | 9.66 Million | 30.3 Million | 4.48 Million | 4.96 Million |
| Cash at end of period | 12.12 Million | 9.66 Million | 30.3 Million | 1.33 Million |
| Capital Expenditure | -1.12 Million | -786 Thousand | -1.25 Million | -545 Thousand |
| Effect of forex changes on cash | - | 20.58 Million | -26.94 Million | - |
| Net cash flow / Change in cash | 2.46 Million | -20.63 Million | 25.81 Million | -3.63 Million |
| Free Cash Flow | -51.16 Million | -33.09 Million | -23.95 Million | -1.22 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.33 Million | -13.21 Million | -59.03 Million | -35.5 Million | -1.28 Million | -13.97 Million |
| Depreciation & Amortization | 270 Thousand | 188 Thousand | 702 Thousand | 202 Thousand | 500 Thousand | 150 Thousand |
| Deferred income taxes | - | - | 11.08 Million | 11.68 Million | - | -145 Thousand |
| Stock-based compensation | 1.27 Million | 1.08 Million | 1.4 Million | 1 Million | 260 Thousand | 68 Thousand |
| Change in working capital | -6.38 Million | -483 Thousand | 740 Thousand | 3.97 Million | -4.56 Million | 1.94 Million |
| Other non-cash items | 875 Thousand | 4.06 Million | -4.94 Million | 9.79 Million | -31.1 Million | 2.72 Million |
| Investing Cash Flow | -60 Thousand | -66 Thousand | -2.12 Million | -700 Thousand | -9.54 Million | -30 Thousand |
| Investments in PPE | -60 Thousand | -66 Thousand | -1.12 Million | -700 Thousand | -421 Thousand | -30 Thousand |
| Acquisitions | - | - | -1 Million | -1 Million | - | - |
| Investment purchases | - | - | - | - | 425.41 Thousand | -191 Thousand |
| Sales/Maturities of investments | - | - | - | - | -8.47 Million | - |
| Other Investing Activities | - | - | -1 Million | 672 Thousand | -1 Million | 1000.00 |
| Financing Cash Flow | 25.99 Million | 3.12 Million | 54.62 Million | 43 Thousand | 61.74 Million | 6.4 Million |
| Debt repayment | -22.38 Million | -22 Thousand | -87 Thousand | -22 Thousand | -1.07 Million | -21 Thousand |
| Dividends payments | -10.9 Thousand | - | - | - | - | - |
| Common Stock Repurchased | - | - | -20 Thousand | -20 Thousand | 8.47 Million | -8.47 Million |
| Common Stock Issuance | 3.6 Million | 3.14 Million | 17.88 Million | 85 Thousand | 17.79 Million | - |
| Other Financing Activities | -2.58 Million | 3.14 Million | 35.73 Million | 65 Thousand | 36.53 Million | 6.42 Million |
| Accounts receivables | -429 Thousand | -723 Thousand | -1.97 Million | -502 Thousand | -940 Thousand | -502 Thousand |
| Accounts payables | -2.35 Million | -305 Thousand | 2.83 Million | 5.61 Million | -2.72 Million | 2.11 Million |
| Inventory | -531 Thousand | -368 Thousand | -1.07 Million | -915 Thousand | -107 Thousand | 199 Thousand |
| Other working capital | -3.06 Million | 913 Thousand | 953 Thousand | -218 Thousand | 1.02 Million | 135 Thousand |
| Cash at beginning of period | 3.97 Million | 12.12 Million | 9.66 Million | 21.63 Million | 103.97 Thousand | 7.01 Million |
| Cash at end of period | 16.48 Million | 4.32 Million | 12.12 Million | 12.12 Million | 21.38 Million | 4.15 Million |
| Capital Expenditure | -60 Thousand | -66 Thousand | -1.12 Million | -700 Thousand | -421 Thousand | -30 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | 2.8 Million |
| Net cash flow / Change in cash | 12.51 Million | -7.8 Million | 2.46 Million | -9.5 Million | 21.27 Million | -2.85 Million |
| Free Cash Flow | -13.48 Million | -10.93 Million | -51.16 Million | -9.54 Million | -40.6 Million | -9.25 Million |
GDEN
TRRGF
MHN
TRATF
1336
SES